Trials / Completed
CompletedNCT00061776
NGX-4010 for the Treatment of Postherpetic Neuralgia
A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- NeurogesX · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is determine if an investigational drug, NGX-4010 (high-concentration capsaicin dermal patches) is effective in treating pain associated with post-herpetic neuralgia (PHN).
Detailed description
Participants will be randomly assigned to receive initial treatment according to one of three doses (application durations), and will receive either NGX-4010 patch (high-concentration capsaicin) or matching control (low-concentration capsaicin). Participants who complete the study evaluations for 12 weeks will have the option of receiving up to 3 additional open-label re-treatments over 1 year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capsaicin Dermal Patch |
Timeline
- First posted
- 2003-06-04
- Last updated
- 2008-03-06
Locations
28 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00061776. Inclusion in this directory is not an endorsement.